The Prostate

Understanding How Individual Cancer Cells Resist Enzalutamide Treatment

Updated

Abstract

Approximately 10% of the LNCaP prostate cancer cell population expressed low or no androgen receptor (AR).

  • Most LNCaP cells expressed the androgen receptor and were sensitive to enzalutamide.
  • A small subpopulation with low or no AR expression demonstrated a distinct gene expression profile and signaling pathways.
  • This AR-low subpopulation showed a strong transcriptional response associated with castration-resistant prostate cancer (CRPC).
  • Functional tests confirmed that AR-low cells exhibited resistance to enzalutamide in both laboratory and animal models.
  • In vivo studies indicated that AR-low cells were selected for survival while AR-positive cells were eliminated during enzalutamide treatment.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

The authors declare no competing interests.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free